Breaking Typhoon Dolphin Approaches Japan’s Southern Islands, Disrupting Travel and Prompting Evacuations Indianapolis Colts Sign Jonathan Taylor to Two-Year Contract Extension FDA Approves First mRNA Flu Vaccine for Individuals 50 and Older U.S.-Mexico Border Wall Project Continues Over a Decade After Initial Pledge Health Workers Strike Amidst Growing Ebola Outbreak in Democratic Republic of Congo

Friday August 7, 2026

Reporter

Insilico Medicine

4Articles Published

5Communities Covered

Published Articles

Press Release

AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging

Aug 5

Press Release

Insilico Medicine Launches the Industry’s First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science

Jul 30

Press Release

Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma

Jul 29

Press Release

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Jul 27